Transplatin derivatives as anticancer agents
US-9974765-B1 · May 22, 2018 · US
Method for inhibiting cancer cell growth with a transplatin complex
US10172823B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-10172823-B1 |
| Application number | US-201815966174-A |
| Country | US |
| Kind code | B1 |
| Filing date | Apr 30, 2018 |
| Priority date | Sep 26, 2017 |
| Publication date | Jan 8, 2019 |
| Grant date | Jan 8, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention is directed to platinum(II) thione complexes of formula (I) and to methods of treating cancer using these complexes.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for inhibiting cell growth or proliferation, comprising: administering a chemotheraputic treatment to a subject having breast or lung cancer, contacting a neoplastic eukaryotic cell of the subject with a pharmaceutical composition comprising a platinum(II) thione complex represented by Formula (1): wherein R 1 and R 2 are each, independently, a hydrogen or a C 1 -C 3 alkyl group, a is 1, 2 or 3; and X is nitrate, fluoride, chloride, bromide, iodide, or acetate. 2. The method of claim 1 that comprises administering, to the subject, trans-[Pt(NH 3 ) 2 (Imt) 2 ].2NO 3 (Complex 1), trans-[Pt(NH 3 ) 2 (MeImt) 2 ]. 2NO 3 (Complex 2), trans-[Pt(NH 3 ) 2 (Me 2 Imt) 2 ]. 2NO 3 (Complex 3), trans-[Pt(NH 3 ) 2 (Et 2 Imt) 2 ]. 2NO 3 (Complex 4), trans-[Pt(NH 3 ) 2 (PrImt) 2 ]. 2NO 3 (Complex 5), trans-[Pt(NH 3 ) 2 (iPrImt) 2 ]. 2NO 3 (Complex 6), or trans-[Pt(NH 3 ) 2 (iPr 2 Imt) 2 ].2 NO 3 (Complex 7). 3. The method of claim 1 that comprises administering, to the subject, trans-[Pt(NH 3 ) 2 (EtDiaz) 2 ]. 2NO 3 (Complex 8). 4. The method of claim 1 that comprises administering, to the subject, trans-[Pt(NH 3 ) 2 (Diap) 2 ]. 2NO 3 (Complex 9). 5. The method of claim 1 , wherein the platinum(II) thione complex is administered, to the subject, parenterally. 6. The method of claim 1 , wherein the pharmaceutical composition is administered, to the subject, intravenously. 7. The method of claim 1 , wherein the platinum(II) thione complex is administered, to the subject, into a tumor or into a site infiltrated by cancer cells.
Assignees
Inventors
Classifications
- A61K31/282Primary
Platinum compounds · CPC title
not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin · CPC title
without a metal-carbon linkage · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10172823B1 cover?
- The invention is directed to platinum(II) thione complexes of formula (I) and to methods of treating cancer using these complexes.
- Who is the assignee on this patent?
- Univ King Fahd Pet & Minerals
- What technology area does this patent fall under?
- Primary CPC classification A61K31/282. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).